| Identification | Back Directory | [Name]
L-NORADRENALINE HYDROCHLORIDE | [CAS]
329-56-6 | [Synonyms]
aktaminhydrochloride
levophedhydrochloride
L-ARTERENOL HYDROCHLORIDE
(-)-ARTERENOL HYDROCHLORIDE
L-NORADRENALINE HYDROCHLORIDE
L-NOREPINEPHRINE HYDROCHLORIDE
[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]azanium chloride
[2-(3,4-dihydroxyphenyl)-2-hydroxy-ethyl]azanium chloride
[2-(3,4-dihydroxyphenyl)-2-hydroxy-ethyl]ammonium chloride
(R)-4-(2-Amino-1-hydroxyethyl)benzene-1,2-diol hydrochloride
L-alpha-(aminomethyl)-3,4-dihydroxybenzyl alcohol hydrochloride
alpha-(aminomethyl)-3,4-dihydroxy-,hydrochloride,(-)-benzylalcoho
1,2-Benzenediol, 4-[(1R)-2-amino-1-hydroxyethyl]-, hydrochloride (1:1)
Racepinephrine Hydrochloride (30 mg) ((RS)-4-(1-hydroxy-2-(methylamino)ethyl)benzene-1,2-diol hydrochloride) | [EINECS(EC#)]
222-395-0 | [Molecular Formula]
C8H12ClNO3 | [MDL Number]
MFCD00064560 | [MOL File]
329-56-6.mol | [Molecular Weight]
205.64 |
| Chemical Properties | Back Directory | [Appearance]
White or brownish-white, crystalline powder. | [Melting point ]
~150 °C (dec.)
| [alpha ]
D25 -40° (c = 6) | [storage temp. ]
2-8°C
| [solubility ]
Very soluble in water, slightly soluble in ethanol (96 per cent). It becomes coloured on exposure to air and light. | [form ]
Solid | [color ]
X-form-crystals | [Uses]
Alpha-adrenoceptor agonist. |
| Hazard Information | Back Directory | [Chemical Properties]
White or brownish-white, crystalline powder. | [Safety Profile]
Poison by ingestion,subcutaneous, and intraduodenal routes. When heated todecomposition it emits very toxic fumes of HCl and NOx. | [in vivo]
Norepinephrine hydrochloride can be used to induce cardiomyopathy[5][6]
Induced Cardiomyopathy Model[5][6] Background Norepinephrine hydrochloride is a potent growth factor for cardiomyocytes. Long-term infusion of subhyperbaric doses of Norepinephrine hydrochloride in animals can cause increases in myocardial mass and left ventricular wall thickness. Norepinephrine hydrochloride activates the Raf-1 kinase/MAP kinase cascade through α1- and β-adrenergic stimulation, and signaling pathways from both receptors synergistically induce cardiomyocyte hypertrophy.
Specific Modeling Methods
Rat: Spragues-Dawley rats ? adult (6 months old) ? male
Administration: Continuously injected via an osmotic minipump ? 100 μg/kg/h or 200 μg/kg/h (Norepinephrine)
Modeling Indicators Molecular changes: Left ventricular Dnmt activity ↑; ROS generation ↑; lactate dehydrogenase release ↑; dystrophin expression ↑; FHL2 protein expression ↓
Gene Expression: Expression of Dnmt1, 3a, and 3b ↑; mRNA expression of fetal genes ANP, BNP, and βMHC in left ventricle ↑
Phenotypic observation: Myocardial infarction area ↑; blood pressure continues to rise; left ventricular mass ↑; left ventricular development pressure ↓; cardiac contractility ↓. Cardiac hypertrophy.
Correlated Product(s): / Opposite Product(s): 5-Aza-2’-deoxycytidine (HY-A0004), Prazosin (HY-B0193), Propranolol (HY-B0573B) | [IC 50]
α1-adrenergic receptor; α2-adrenergic receptor; Beta-1 adrenergic receptor; Microbial Metabolite; Human Endogenous Metabolite | [Purification Methods]
Recrystallise arterenol from isoPrOH and store it in the dark as it is oxidised under light (see preceding entry). [Tullar J Am Chem Soc 70 2067 1948, Beilstein 13 III 2382.] |
|
|